Related Experiment Video
Updated: Jul 17, 2026

Microbial Communities in Nature and Laboratory - Interview
Published on: May 28, 2007
The experience with voluntary genomic data submissions at the FDA and a vision for the future of the voluntary data
1Genomics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. michael.orr@fda.hhs.gov
Abstract:
Drug developers have been using genomic information in drug development strategies for a number of years, but it was unclear how this information would be reviewed by the Food and Drug Administration (FDA). In order to evaluate the regulatory impact of genomic data in current drug development, a workshop was held in May 2002 to discuss aspects surrounding genomic data submission to the FDA (Figure 1).
More Related Videos
Related Concept Videos
Genomics
Purpose of Health Records II
Bioequivalence studies: Biowaivers
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Drug Regulation

